86 related articles for article (PubMed ID: 22176792)
21. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
22. Update on the metabolic effects of steroidal contraceptives.
Sondheimer SJ
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
[TBL] [Abstract][Full Text] [Related]
23. Comparison of levonorgestrel and copper releasing intrauterine contraceptive device on body iron stores and menstrual bleeding patterns: experience on Indian women.
Rana M; Saxena P; Firdous N
Eur Rev Med Pharmacol Sci; 2012 Feb; 16(2):230-4. PubMed ID: 22428475
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
25. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
Freeman EW; Halbreich U; Grubb GS; Rapkin AJ; Skouby SO; Smith L; Mirkin S; Constantine GD
Contraception; 2012 May; 85(5):437-45. PubMed ID: 22152588
[TBL] [Abstract][Full Text] [Related]
26. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
Halbreich U; Freeman EW; Rapkin AJ; Cohen LS; Grubb GS; Bergeron R; Smith L; Mirkin S; Constantine GD
Contraception; 2012 Jan; 85(1):19-27. PubMed ID: 22067793
[TBL] [Abstract][Full Text] [Related]
27. The vaginal contraceptive pill.
Coutinho E
IPPF Med Bull; 1985 Feb; 19(1):2-3. PubMed ID: 12339969
[TBL] [Abstract][Full Text] [Related]
28. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol.
Torgrimson BN; Meendering JR; Kaplan PF; Minson CT
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2874-80. PubMed ID: 17277029
[TBL] [Abstract][Full Text] [Related]
29. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial.
Kaneshiro B; Edelman A; Carlson N; Morgan K; Nichols M; Jensen J
Obstet Gynecol; 2010 Jun; 115(6):1141-1149. PubMed ID: 20502283
[TBL] [Abstract][Full Text] [Related]
30. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
31. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.
Sulak PJ; Smith V; Coffee A; Witt I; Kuehl AL; Kuehl TJ
Obstet Gynecol; 2008 Sep; 112(3):563-71. PubMed ID: 18757653
[TBL] [Abstract][Full Text] [Related]
32. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
33. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
Winkler UH; Ferguson H; Mulders JA
Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
[TBL] [Abstract][Full Text] [Related]
34. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
Gemzell-Danielsson K; Schellschmidt I; Apter D
Fertil Steril; 2012 Mar; 97(3):616-22.e1-3. PubMed ID: 22222193
[TBL] [Abstract][Full Text] [Related]
35. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
[TBL] [Abstract][Full Text] [Related]
36. [A comparative clinical study of the effects of three types of low-dose estrogen/progestogen oral contraceptives].
Chen JK
Shengzhi Yu Biyun; 1987 May; 7(2):11-6. PubMed ID: 12268918
[TBL] [Abstract][Full Text] [Related]
37. Oral contraceptive tolerance: does the type of pill matter?
Moreau C; Trussell J; Gilbert F; Bajos N; Bouyer J
Obstet Gynecol; 2007 Jun; 109(6):1277-85. PubMed ID: 17540798
[TBL] [Abstract][Full Text] [Related]
38. Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system.
Heikinheimo O; Inki P; Kunz M; Gemzell-Danielsson K
Hum Reprod; 2010 Jun; 25(6):1423-7. PubMed ID: 20378611
[TBL] [Abstract][Full Text] [Related]
39. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
Upton GV; Corbin A
Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
[TBL] [Abstract][Full Text] [Related]
40. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Gaussem P; Alhenc-Gelas M; Thomas JL; Bachelot-Loza C; Remones V; Ali FD; Aiach M; Scarabin PY
Thromb Haemost; 2011 Mar; 105(3):560-7. PubMed ID: 21225090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
